US equities |
MU $1,097.39 ▲+0.00% NVDA $230.86 ▲+0.00% SNDK $1,787.69 ▲+0.00% STX $945.57 ▲+0.00% WDC $462.56 ▲+0.00% NKE $35.15 ▲+0.00% MSTR $160.50 ▲+0.00% INTC $120.00 ▲+0.00%
FinancialContent

Articles published by Sandoz Group

News headline image
Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz reports strong FY 2024 results and Q4 2024 sales
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Francisco Ballester to retire; Peter Stenico appointed President Region International
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz reports third-quarter and nine-month 2024 sales
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolio
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz reports second-quarter sales and half-year 2024 results
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz reports first quarter 2024 sales
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY
News headline image
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines
From Sandoz Group
Via GlobeNewswire
Tickers SDZNY